A5003059789- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Cancer Cells and Metastasis
- Intraperitoneal and Appendiceal Malignancies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Research and Treatments
- Colorectal Cancer Surgical Treatments
- Immune Cell Function and Interaction
- Colorectal and Anal Carcinomas
- Ovarian cancer diagnosis and treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer-related molecular mechanisms research
- Multiple and Secondary Primary Cancers
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Sarcoma Diagnosis and Treatment
- Mycobacterium research and diagnosis
Université de Rouen Normandie
2016-2025
Inserm
2014-2024
Normandie Université
2017-2024
Centre Hospitalier Universitaire de Rouen
2012-2024
Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers
2019-2022
Hôpital Charles-Nicolle
2007-2021
Institute for Research and Innovation in Biomedicine
2010-2016
Hôpitaux Universitaires de Strasbourg
2016
San Salvatore Hospital
2011-2012
University of L'Aquila
2011-2012
The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy has recently been suggested. In our study, 59 a chemotherapy-refractory MCRC were included and clinical response was evaluated according to evaluation criteria solid tumours (RECIST). Tumours screened for mutations using first direct sequencing, then two sensitive methods based on SNaPshot PCR-ligase chain reaction (LCR) assays. Clinical gene the Fisher exact test....
Purpose The antiepidermal growth factor receptor antibody cetuximab shows activity in irinotecan-refractory metastatic colorectal cancer (mCRC), mainly wild-type KRAS tumors. Cetuximab may also exert antitumor effects through antibody-dependent cell-mediated cytotoxicity (ADCC) which Fc portion interacts with receptors (FcγRs) expressed by immune cells. ADCC is influenced FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms that are clinically relevant follicular lymphoma breast treated rituximab...
Colorectal cancers with microsatellite instability (MSI) represent 15% of all colorectal cancers, including Lynch syndrome as the most frequent hereditary form this disease. Notably, MSI have a higher density tumor-infiltrating lymphocytes (TIL) than other cancers. This feature is thought to reflect accumulation frameshift mutations in sequences that are repeated within gene coding regions, thereby leading synthesis neoantigens recognized by CD8(+) T cells. However, there has yet be clear...
The dual oxidase (Duox)2 flavoprotein is strongly expressed in the thyroid gland, where it plays a critical role synthesis of hormones by providing thyroperoxidase with H 2 O . DUOX2 mRNA was recently detected RT-PCR and in-situ hybridization experiments other tissues, such as rat colon human epithelial cells from salivary excretory ducts rectal glands. We examined Duox2 expression at protein level throughout porcine digestive tract colon. Western blot analysis identified same two molecular...
The discovery of a targeted therapeutic compound along with its companion predictive biomarker is major goal clinical development for personalized anticancer therapy to date. Here we present evidence the value TLR3 expression by tumor cells efficacy Poly (A:U) dsRNA in 194 breast cancer patients enrolled randomized trial. Adjuvant treatment double-stranded RNA (dsRNA) was associated significant decrease risk metastatic relapse positive but not TLR3-negative cancers. Moreover, show functional...
The direct comparison of CA19.9, circulating tumour cells (CTCs) and DNA (ctDNA) using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has never been performed for the diagnosis solid pancreatic tumours (SPTs).We included 68 patients with a SPT referred EUS-FNA. CTCs were analysed size-based platform ctDNA digital PCR. sensitivity, specificity, negative positive predictive values evaluated each marker their combination.SPTs corresponded to 58 malignant (52 adenocarcinoma (PA) 6...
Background Development of tumours such as adrenocortical carcinomas (ACC), choroid plexus (CPT) or female breast cancers before age 31 multiple primary belonging to the Li-Fraumeni (LFS) spectrum is, independently familial history, highly suggestive a germline TP53 mutation. The aim this study was determine contribution de novo and mosaic mutations LFS. Methods results Among 328 unrelated patients harbouring mutation identified by Sanger sequencing and/or QMPSF, we could show that had...
Background and Objectives It is now established that liver resection beneficial for metastases from colorectal cancer. Nevertheless, a surgical margin estimated at less than 10 mm preoperative imaging considered an absolute contraindication to surgery by some, relative others. The true impact of the width on prognosis unclear. Methods From 1984 1996, 196 patients underwent curative hepatectomy were studied prospectively. Surgery was be (or complete R0 resection) mortality avoided. Of these...
The management of proctitis in patients who have undergone very-high-dose conformal radiotherapy is extremely challenging. fibrosis-necrosis, fistulae, and hemorrhage induced by pelvic overirradiation an impact on morbidity. Augmenting tissue repair the use mesenchymal stem cells (MSCs) may be important advance treating radiation-induced toxicity. Using a preclinical pig model, we investigated effect autologous bone marrow-derived MSCs high-dose proctitis. Irradiated pigs received repeated...
Sporadic or hereditary colorectal cancer (CRC) with microsatellite instability (MSI) is frequently characterized by inflammatory lymphocytic infiltration and tends to be associated a better outcome than stable (MSS) CRC, probably reflecting more effective immune response. We investigated mechanisms in 48 MSI CRCs 62 MSS analyzing: (1) the expression of cytokines using Bio-Plex multiplex cytokine assays, (2) situ response immunohistochemical analysis antibodies against CD3 (T lymphocytes),...
Lung cancers are broadly divided into two categories: non-small-cell lung carcinoma (NSCLC), which accounts for 80–85% of all cancer cases, and small-cell (SCLC), covers the remaining 10–15%. Recent advances in biology genomics research have allowed an in-depth characterization that revealed new therapy targets (EGFR, ALK, ROS, KRAS mutations) potential revealing even more biomarkers diagnostic, prognostic, targeted therapies. A source is represented by non-coding RNAs, especially microRNAs...
Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines metastatic non-squamous non-small-cell lung cancer, and considered mandatory European countries. However, practice, challenges are often faced when carrying out routine biomarker testing, including access to inadequate tissue samples long turnaround times (TATs).To evaluate the real-world EGFR testing practices of pathology laboratories, online survey was set up validated by Pulmonary...